Mumbai: Pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from US FDA for the successful inspection of its Nagpur facility. The inspection was conducted in May 2018.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8^th largest generics pharmaceutical company both in terms of market capitalization (30^th June 2018, Bloomberg) and revenues (31^st March 2018, Bloomberg LTM) globally. The Company is the 4^th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3^rd largest Indian pharmaceutical company by global revenues (31^st March 2018, Bloomberg LTM); 6^th largest generic pharmaceutical player in Japan and 5^th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31^st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055. 

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

*Safe Harbor Statement